| CEO: | Anders Lundstrom |
| Independent Non-Executive Director: | Peter Llewellyn-Davies |
| Independent Non-Executive Director: | Fabiana Lacerca Allen |
| Non-Executive Chairman: | Hans-Peter Hasler |
| Non-Executive Dir: | Christian Schweiger, Rudolf Widmann |
| Address: | Northern Design Centre, Baltic Business Quarter, Gateshead Quays, United Kingdom, NE8 3DF |
| Phone: | +44 (0) 191 511 8500 |
| Website: | http://www.shieldtherapeutics.com/ |
| Sector: | Pharma and Biotech(LSE) |
| Index: | FTSE AIM All-Share |
| ISIN: | GB00BYV81293 |
| Currency | UK Pounds |
| Share Price | 4.50p |
| Change Today | 0.30p |
| % Change | 7.14 % |
| 52 Week High | 12.20 |
| 52 Week Low | 3.73 |
| Volume | 2,810,605 |
| Shares Issued | 1,069.91m |
| Market Cap | £48.15m |
| Beta | 0.03 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:29 | 109,440 @ 4.56p |
| 16:25 | 975 @ 4.58p |
| 16:19 | 20,000 @ 4.56p |
| 16:19 | 100 @ 4.60p |
| 16:19 | 109,409 @ 4.57p |
You are here: research